Abstract: Provided are a positioning reference signal (PRS) transmission method and apparatus, and a storage medium. A PRS sending end presets PRS blocks having the same number as the number of shaped beams, a corresponding PRS sequence in each PRS block by using a preset sequence generation rule, and each PRS block containing the corresponding PRS sequence is sent according to a preset sending order of the PRS blocks in a polling manner through a shaped beam corresponding to the each PRS block. A PRS receiving end acquires a first PRS block sent by the PRS sending end; and when the first PRS block contains a block index, a sending index of a shaped beam corresponding to the first PRS block corresponding to the block index is determined according to preset correspondence; or when the first PRS block contains no block index, a sending index of a shaped beam corresponding to the first PRS block is determined according to a preset calculation rule.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following structure. The cyclic dinucleotide analogue can be used as a regulator of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, and infectious diseases. In addition, the STING regulator can also be used as a vaccine adjuvant.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.

Abstract: Provided are a disparity estimation method and apparatus, an image processing device, and a storage medium. The method includes: processing input images based on a first network model to obtain a direct cost volume of the input images, where the input images include a first image and a second image, and the first network model includes a convolutional neural network, a pyramid convolutional network, and a spatial pyramid pooling layer; processing the input images based on a second network model to obtain an associated cost volume of the input images, where the second network model includes a residual network; determining an estimated cost of the input images according to the associated cost volume and the direct cost volume; and calculating an estimated disparity corresponding to the first image and the second image according to the estimated cost.

Abstract: Provided is a positioning reference signal generation method, which includes the following steps: allocating a time-frequency resource to a positioning reference signal, where the time-frequency resource includes at least two consecutive symbols; and according to generation information of the positioning reference signal and the time-frequency resource, taking the at least two consecutive symbols as a combined PRS symbol to generate the positioning reference signal which is consecutive in a time domain based on a preset generation mode. Further provided are a positioning reference signal generation apparatus, a base station and a readable storage medium.

Abstract: A cloud server may estimate an amount of computing resources needed to perform a computing task, generate a first proposal indicating first parameters for the server to perform the task based on the estimate, obtain, from one or more edge servers, second proposals indicating second parameters for the edge servers to perform the task, transmit the first proposal and the second proposals to a vehicle, upon receiving acceptance of the first proposal, perform the task based on the first parameters, and transmit data associated with performance of the task to the vehicle, and upon receiving acceptance of one of the second proposals, transmit the acceptance to the edge server associated with the accepted proposal.

Abstract: The disclosure includes embodiments that provide a switching decision for vehicle computational offloading to a roadside edge server. A method includes causing a sensor set of a connected vehicle to determine a current driving context of the connected vehicle. The method includes comparing the current driving context to a set of historical data to determine a predicted latency for using offboard computing resources of an edge server. The method includes determining that the predicted latency for using the offboard computing resources satisfies a threshold for the predicted latency. The method includes executing a switching decision that includes deciding to use the offboard computing resources of the edge server. The method includes causing the edge server to wirelessly provide digital data generated by the edge server responsive to a calculation. The method includes modifying an operation of the onboard vehicle computer based on the digital data.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

Abstract: An example operation includes one or more of receiving, by a vehicle, a software update from a first node, responsive to the software update encountering an issue, ceasing, by the vehicle, the software update resulting in an initial portion of the software update being received by the vehicle, requesting, by the vehicle, a remaining portion of the software update, and receiving, by the vehicle, the remaining portion of the software update from a second node.

Abstract: The disclosure relates to bifunctional KRAS-modulating compounds having the structure K-L-T, where K is a targeting group that binds specifically to a KRAS protein (mutant or wild-type), T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects K and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of KRAS protein (mutant or wild-type) in a cell and are thus useful for treating, inhibiting, and preventing KRAS-associated diseases, disorders and conditions, including cancers.

Abstract: The disclosure relates to KRAS inhibitor compounds having the structure of Formula (I), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRAS-associated diseases, disorders and conditions.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Abstract: Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Abstract: A camera view share system is provided. The camera view share system includes a road-side unit. The road-side unit includes a controller configured to receive a request for a bird-eye-view map from an ego vehicle, the bird-eye-view map including a plurality of vehicles, transmit the bird-eye-view map to the ego vehicle, receive a selection of a target vehicle among the plurality of vehicles from the ego vehicle, and transmit a camera feed related to the target vehicle to the ego vehicle.

Abstract: A system for communication-aware federated learning includes a server and edge nodes. Each of the edge nodes trains a machine learning model using first local data obtained by sensors of corresponding edge node. Each of the edge nodes obtains network bandwidth for a channel between corresponding edge node and the server. One or more of the edge nodes determines a level of compression based on the bandwidth for the channel, compresses the trained machine leaning model based on the determined level of compression, and transmits the compressed trained machine learning model to the server. The server decompresses the compressed trained machine learning models and aggregates the decompressed trained machine learning models to obtain the aggregated machine learning model, and transmits the aggregated machine learning model to each of the edge nodes. Each of the edge nodes receives the aggregated machine learning model from the server.

Abstract: Provide are a positioning reference signal generation method and apparatus, a communication system and a storage medium. The method includes: generating a positioning frequency domain sequence according to time-frequency resource information and system configuration information, where the time-frequency resource information includes the number Nprsslot of allocated system symbols consecutive in time, and the system configuration information includes positioning subcarrier spacing ?fprs; and generating, based on the positioning frequency domain sequence, positioning time domain data consecutive in a time period of the Nprsslot consecutive system symbols.

Abstract: A system for contribution-aware federated learning is provided. The system includes a server and a plurality of vehicles. Each of the plurality of vehicles includes a controller programmed to: train a local machine learning model using first local data; obtain metadata for hardware elements of corresponding vehicle; transmit the trained local machine learning model and the metadata to a server; receive an aggregated machine learning model from the server; and train the aggregated machine learning model using second local data. The server generates the aggregated machine learning model based on the trained local machine learning models and the metadata received from the plurality of vehicles.

Abstract: The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-associated diseases, disorders and conditions.

Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I? and I?? or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.